Literature DB >> 17557128

Future aspects of botulinum neurotoxins.

K R Aoki1.   

Abstract

The future of botulinum neurotoxin (BoNT) development is expected to proceed along two lines: the development of novel indications and the development of novel products. New indications will likely be based on the neuromuscular mode of action of BoNTs, as well as action on primary sensory fibers and other neuronal types. Novel BoNT products may be designed for increased specificity or enhanced duration. As new products enter the market, it will be important for each to demonstrate efficacy and safety. Unfortunately, the future of BoNTs will also likely include attempts to obtain and distribute unlicensed and illegal BoNT products that may pose substantial risks to patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17557128     DOI: 10.1007/s00702-007-0758-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  57 in total

1.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

Authors:  M J Welch; J R Purkiss; K A Foster
Journal:  Toxicon       Date:  2000-02       Impact factor: 3.033

2.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Authors:  D Ranoux; C Gury; J Fondarai; J L Mas; M Zuber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

3.  Effect of botulinum toxin A on facial wrinkle lines in Koreans.

Authors:  Helen Lew; Young Soo Yun; Sang Yeul Lee; Sung Joo Kim
Journal:  Ophthalmologica       Date:  2002 Jan-Feb       Impact factor: 3.250

Review 4.  Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.

Authors:  D Dressler; M Hallett
Journal:  Eur J Neurol       Date:  2006-02       Impact factor: 6.089

5.  Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.

Authors:  Katalin Bihari
Journal:  Curr Med Res Opin       Date:  2005-03       Impact factor: 2.580

6.  Development of resistance to botulinum toxin type A in patients with torticollis.

Authors:  P Greene; S Fahn; B Diamond
Journal:  Mov Disord       Date:  1994-03       Impact factor: 10.338

7.  Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons.

Authors:  Judy L Morris; Phillip Jobling; Ian L Gibbins
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08-29       Impact factor: 4.733

8.  Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Authors:  Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Maria Gabriella Ceravolo
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

9.  Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1.

Authors:  L A Birder; Y Nakamura; S Kiss; M L Nealen; S Barrick; A J Kanai; E Wang; G Ruiz; W C De Groat; G Apodaca; S Watkins; M J Caterina
Journal:  Nat Neurosci       Date:  2002-09       Impact factor: 24.884

10.  Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain.

Authors:  John A Chaddock; John R Purkiss; Frances C G Alexander; Sarah Doward; Sarah J Fooks; Lorna M Friis; Yper H J Hall; Elizabeth R Kirby; Nicola Leeds; Hilary J Moulsdale; Anthony Dickenson; G Mark Green; Wahida Rahman; Rie Suzuki; Michael J Duggan; Conrad P Quinn; Clifford C Shone; Keith A Foster
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

View more
  7 in total

1.  [Types of topical treatment for peripheral neuropathic pain : Mechanism of action and indications].

Authors:  R Baron; F Mahn
Journal:  Schmerz       Date:  2010-08       Impact factor: 1.107

2.  Association of antinociceptive action of botulinum toxin type A with GABA-A receptor.

Authors:  V Drinovac; L Bach-Rojecky; Z Lacković
Journal:  J Neural Transm (Vienna)       Date:  2014-01-14       Impact factor: 3.575

Review 3.  Targeted secretion inhibitors-innovative protein therapeutics.

Authors:  Foster Keith; Chaddock John
Journal:  Toxins (Basel)       Date:  2010-12-03       Impact factor: 4.546

Review 4.  Botulinum Toxin for Neuropathic Pain: A Review of the Literature.

Authors:  Hyun-Mi Oh; Myung Eun Chung
Journal:  Toxins (Basel)       Date:  2015-08-14       Impact factor: 4.546

5.  The analgesic effect of intraarticular OnabotulinumtoxinA in a female murine model of collagenase induced chronic degenerative monoarthritis.

Authors:  Nicole Blanshan; Maren L Mahowald; Christopher Dorman; Sandra Frizelle; Hollis E Krug
Journal:  Toxicon       Date:  2018-11-22       Impact factor: 3.033

6.  The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.

Authors:  Jiangshan Wei; Xiangyu Zhu; Guang Yang; Jun Shen; Peng Xie; Xiaohua Zuo; Lei Xia; Qiu Han; Ying Zhao
Journal:  Brain Behav       Date:  2019-09-21       Impact factor: 2.708

7.  The Effect of Botulinum Neurotoxin Serotype a Heavy Chain on the Growth Related Proteins and Neurite Outgrowth after Spinal Cord Injury in Rats.

Authors:  Ya-Fang Wang; Fu Liu; Jing Lan; Juan Bai; Xia-Qing Li
Journal:  Toxins (Basel)       Date:  2018-02-02       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.